Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PharmaTher Holdings Ltd ( (TSE:PHRM) ) has shared an announcement.
PharmaTher Holdings Ltd. announced an update on its ketamine program for treating levodopa-induced dyskinesia (LID) in Parkinson’s disease, targeting a significant market opportunity in the U.S. The company is leveraging the 505(b)(2) regulatory pathway to expedite the development process, aiming to reduce risk, cost, and time. With patent coverage until 2036 and active pharmaceutical partnering discussions, PharmaTher is preparing for a Phase 3 clinical study to evaluate the efficacy and safety of ketamine for LID-PD. The company highlights ketamine’s strong biological rationale and previous clinical evidence supporting its potential effectiveness, positioning it as a promising candidate in a market projected to reach up to US$2.2 billion.
Spark’s Take on TSE:PHRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.
PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.
To see Spark’s full report on TSE:PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine. The company is engaged in the development of ketamine-based treatments, particularly targeting conditions such as levodopa-induced dyskinesia in Parkinson’s disease patients.
Average Trading Volume: 320,195
Technical Sentiment Signal: Sell
Current Market Cap: C$18.59M
For an in-depth examination of PHRM stock, go to TipRanks’ Overview page.